A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.

Clin Genitourin Cancer 2015 Apr 22;13(2):113-23. Epub 2014 Oct 22.

Medical Oncology, Dana-Farber Cancer Institute and Internal Medicine, Harvard Medical School, Boston, MA. Electronic address:

Background: The PTEN tumor suppressor is frequently lost in CRPC, with activation of Akt-mTOR signaling, driving growth. We conducted a phase I trial of the mTOR inhibitor, everolimus, and docetaxel in CRPC.

Patients And Methods: Eligible patients had progressive, metastatic, chemotherapy-naive CRPC. Patients received everolimus 10 mg daily for 2 weeks and underwent a restaging FDG-PET/computed tomography scan. Patient cohorts were subsequently treated at 3 dose levels of everolimus with docetaxel: 5 mg to 60 mg/m(2), 10 mg to 60 mg/m(2), and 10 mg to 70 mg/m(2). The primary end point was the safety and tolerability of combination therapy.

Results: Accrual was 4 patients at level 1, 3 patients at level 2, and 8 patients at level 3. Common toxicities were hematologic and fatigue. Serum concentrations of everolimus when administered with docetaxel were 1.5 to 14.8 ng/mL in patients receiving 5 mg everolimus and 4.5 to 55.4 ng/mL in patients receiving 10 mg everolimus. Four patients had partial metabolic response (PMR) using FDG-PET, 12 had stable metabolic disease, and 2 had progressive metabolic disease after a 2-week treatment with everolimus alone. Five of 12 evaluable patients experienced a prostate-specific antigen (PSA) reduction ≥ 50% during treatment with everolimus together with docetaxel. All 4 patients with a PMR according to PET imaging experienced a PSA reduction in response to everolimus with docetaxel, and 3 of 4 had PSA declines ≥ 50%.

Conclusion: Everolimus 10 mg daily and docetaxel 60 mg/m(2) was safe in CRPC patients and these were the recommended doses in combination. FDG-PET response might serve as a biomarker for target inhibition by mTOR inhibitors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.08.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418946PMC
April 2015
59 Reads

Publication Analysis

Top Keywords

everolimus docetaxel
20
patients
12
patients level
12
everolimus
11
ng/ml patients
8
treatment everolimus
8
patients receiving
8
everolimus daily
8
receiving everolimus
8
level patients
8
psa reduction
8
docetaxel mg/m2
8
metabolic disease
8
docetaxel patients
8
crpc patients
8
mg/m2 mg/m2
8
docetaxel
7
everolimus 554
4
docetaxel 148
4
148 ng/ml
4

Similar Publications